Fanregratinib vs Pemigatinib
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Cholangiocarcinoma
Shared mechanism: FGFR1/2/3 · full Cholangiocarcinoma pipeline
Fanregratinib · ATLED
Marketed by HUTCHMED
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Pemigatinib · Pemazyre
Marketed by Incyte and partners
NCT02924376 · Phase 2 · completed
This was a non-randomized, open-label, single-arm study with no placebo or active comparator, so responses cannot be separated from the expected course of disease without treatment. The primary endpoint was a clinical tumor-response measure assessed by independent central imaging review, but there was no formal between-group comparison.
Next expected readout: July 2027 · NCT06728410 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Cholangiocarcinoma
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
Fanregratinib: no structured comparison results are available for Cholangiocarcinoma.
Pemigatinib: registry results are on file for Cholangiocarcinoma, but their comparison mappings are not yet available.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Fanregratinib's landscape · Pemigatinib's landscape